Ambry Genetics, a subsidiary of Tempus AI Inc., has announced a significant validation of its CARE Program® for hereditary cancer risk assessment. A peer-reviewed study published in the Journal of the National Comprehensive Cancer Network confirms the program's accuracy in interpreting NCCN Clinical Practice Guidelines with 99.5% accuracy. This reinforces CARE's role as an effective digital risk assessment tool, aiding in the identification of patients who may benefit from genetic testing and personalized care. The program integrates with electronic health records and collects comprehensive medical and family histories directly from patients, facilitating proactive and personalized healthcare. This development supports Ambry Genetics' mission to expand access to genetic services and improve patient outcomes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.